(Q44612900)

4 December 2017

title

Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib (English)

1 reference

gastrointestinal stromal tumor

4 December 2017

main subject

1 reference

5

1 reference

4 December 2017

6

1 reference

4 December 2017

7

Peter Hohenberger

1 reference

4 December 2017

Jens Jakob

1

1 reference

4 December 2017

Chiara Mussi

series ordinal

2

1 reference

4 December 2017

Ulrich Ronellenfitsch

series ordinal

3

1 reference

4 December 2017

Eva Wardelmann

series ordinal

4

1 reference

4 December 2017

publication date

11 September 2012

1 reference

Annals of Surgical Oncology

4 December 2017

published in

1 reference

4 December 2017

volume

20

1 reference

4 December 2017

issue

2

1 reference

4 December 2017

page(s)

586-592

1 reference

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Gastrointestinal stromal tumors of the rectum: Clinical, pathologic, immunohistochemical characteristics and prognostic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Colorectal mesenchymal tumor: a clinicopathologic study of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Surgical margin status and prognosis of gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2647-1

10.1245/S10434-012-2647-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

4 December 2017

1001840407

0 references

1 reference